A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Matthew S. Davids(Dana-Farber Cancer Institute), Alexey V. Danilov(City Of Hope National Medical Center), Richard Ghalie(MEI Pharma (United States)), Carly Roleder(City Of Hope National Medical Center), Sandra E. Wiley(MEI Pharma (United States)), Mary C. Collins(Dana-Farber Cancer Institute), Danielle M. Brander(Duke University), Monzr M. Al Malki(City of Hope), Vijaya Raj Bhatt(Susan Thompson Buffett Foundation), Catherine Diefenbach(NYU Langone Health), Edward C. Dominguez(City Of Hope National Medical Center), Shira Dinner(Dana-Farber Cancer Institute), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Kebede H. Begna(Mayo Clinic), Prabhu Rajagopalan(Mountain Lakes High School), Daniel Nathan Egan(Swedish Medical Center), Nathalie Javidi‐Sharifi(Harvard University), Sameem Abedin(Medical College of Wisconsin)
Cited by 9
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606